<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884245</url>
  </required_header>
  <id_info>
    <org_study_id>PRESCORI</org_study_id>
    <nct_id>NCT02884245</nct_id>
  </id_info>
  <brief_title>Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa</brief_title>
  <acronym>PRESCORI</acronym>
  <official_title>Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa in Women Older Than 38 Years Old Undergoing in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      E2 given in late luteal phase can be extended beyond the onset of menses for a period of at
      least eight days before the start of the stimulation, allowing scheduling of stimulation in
      order to limit oocytes retrievals during weekends .

      Administration of corifollitropin alfa, a Follicule stimulating Hormone (FSH) with extended
      release kinetics, seems particularly interesting for a synchronous recruitment of follicles
      after homogenization of the cohort.

      The objective of this study is to evaluate the impact on the response to ovarian stimulation
      with corifollitropin alfa of E2 scheduling versus no scheduling for women over 38 years, age
      at which declining of ovarian reserve usually begins. The management of these patients in
      terms of organization of the center is also evaluated.

      The scheduling of IVF cycles represents a double benefit. On one hand, to enable a
      &quot;synchronization&quot; of the follicular cohort for a best response and a higher number of mature
      oocytes. On the other hand, a more efficient organization for both the center (avoiding
      retrievals on weekends and public holidays, organize and distribute equally the activity,
      reduce cost operations) and couples (personal and professional organization).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With advanced age, ovarian reserve decreases, follicular cohort becomes heterogeneous under
      the influence of higher FSH rise in late luteal phase. It has been shown that estrogens (E2)
      taken in the late luteal phase homogenized follicular cohort by inhibiting inter cycle FSH
      peak ,and that this inhibition is immediately reversible after discontinuation of treatment .

      E2 given in late luteal phase can also be extended beyond the onset of menses for a period of
      at least eight days before the start of the stimulation, allowing scheduling of stimulation
      in order to limit oocytes retrievals during weekends . A prospective randomized study
      comparing E2 scheduling and no scheduling has shown that there was no difference in birth
      rate in a population of normo-responders women . While in these patients, the number of
      oocytes was not different in the two arms, a recent pilot study founded a significant
      increase in the number of oocytes retrieved after E2 luteal phase priming compared to the
      absence of priming in a population of poor responders .

      In 2013, a report of the French governmental BioMedicine Agency warned about the
      thrombo-embolic risk associated with the use of the contraceptive pill for IVF scheduling,
      especially in women over 35.

      Administration of corifollitropin alfa, an FSH with extended release kinetics, seems
      particularly interesting for a synchronous recruitment of follicles after homogenization of
      the cohort. In the Pursue study, an equivalent efficacy has been shown with the daily
      administration of 300 IU FSH and corifollitropin alfa in patients over 35 years .

      The objective of this study is to evaluate the impact of the response to ovarian stimulation
      with corifollitropin alfa of E2 scheduling versus no scheduling for women over 38 years, age
      at which declining of ovarian reserve usually begins. The management of these patients in
      terms of organization of the center is also evaluated.

      The scheduling of IVF cycles represents a double benefit. On one hand, to enable a
      &quot;synchronization&quot; of the follicular cohort for a best response and a higher number of mature
      oocytes. On the other hand, a more efficient organization for both the center (avoiding
      retrievals on weekends and public holidays, organize and distribute equally the activity,
      reduce cost operations) and couples (personal and professional organization). This can be
      done with pills but there are controversial data on its impact on the chances of birth. It
      has been shown that estrogen scheduling provides opportunities for success equivalent to the
      absence of scheduling for patients with good prognosis . If this study confirms the initial
      hypothesis, it will show that a less favorable public can profit from the benefits of
      scheduling by estrogen on both the organization of the attempt and the chances of pregnancy
      through better ovarian response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of selected oocytes</measure>
    <time_frame>At time of ovarian puncture</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days of pretreatment</measure>
    <time_frame>From inclusion visit date to the beginning of stimulation, up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate</measure>
    <time_frame>From date of inclusion visit until the date of embryo transfer, up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of antagonist</measure>
    <time_frame>From date of stimulation until the date of the trigger, up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The day of the trigger</measure>
    <time_frame>At time of the trigger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol rate</measure>
    <time_frame>8 days from the beginning of stimulation and the day of the trigger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone rate</measure>
    <time_frame>8 days from the beginning of stimulation and the day of the trigger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone rate</measure>
    <time_frame>8 days from the beginning of stimulation and the day of the trigger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicles number &gt; 10 mm</measure>
    <time_frame>8 days from the beginning of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicles number &gt; 14 mm</measure>
    <time_frame>From 1 day before the day of trigger or the day of trigger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes in metaphase 2</measure>
    <time_frame>At time of ovarian puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of embryos with good quality</measure>
    <time_frame>At time of fertilization procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early pregnancy</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>Beta Human chorionic gonadotropin&gt;100 U/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>on ultrasound procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage before 12 weeks of amenorrhea</measure>
    <time_frame>From embryo transfer to 12 weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Arm E2: With estrogens pretreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm S: without estrogens pretreatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No estrogen pretreatment will be delivered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogens</intervention_name>
    <description>The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses</description>
    <arm_group_label>Arm E2: With estrogens pretreatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of 38 years or more

          -  Planned in invitro fertilization or intracytoplasmic sperm injection rank 1 or 2 (rank
             = retrieval with transfer)

          -  With regular cycles from 26 to 35 days

          -  Weight &gt; 50 kg and body mass index&lt; or equal to 32

          -  Affiliation to the general system of French social security and reimbursement for
             fertility problems

        Exclusion Criteria:

          -  Irregular cycles and/or polycystic ovarian syndrome

          -  Previous History of ovarian hyperstimulation syndrome

          -  Rank puncture &gt; 2

          -  Uterine malformation

          -  Presence of hydrosalpinges

          -  Endometriosis stage III or IV
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne GUIVARC'H - LEVEQUE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de la Sagesse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle CEDRIN - DURNERIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Jean Verdier - APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie MASSIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne GUIVARC'H - LEVEQUE, MD</last_name>
    <email>anne.guivarch@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MD DURNERIN, MD</last_name>
      <email>isabelle.cedrin-durnerin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle DURNERIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael GRYNBERG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice SEROKA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie BERNARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire VINOLAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Creteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelle ISSA</last_name>
      <email>amelle.issa@chicreteil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie MASSIN</last_name>
      <email>nathalie.massin@chicreteil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nathalie MASSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène BRY GAUILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud PASQUIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire PIETIN VIALLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annina LOBERSZTAJN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sagesse</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MD GUIVARCH LEVEQUE</last_name>
      <email>anne.guivarch@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Anne GUIVARCH LEVEQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie FROMENTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud BIDET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BROUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic MOY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas LUCAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérique JAFFRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Blockeel C, Engels S, De Vos M, Haentjens P, Polyzos NP, Stoop D, Camus M, Devroey P. Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reprod Biomed Online. 2012 Mar;24(3):272-80. doi: 10.1016/j.rbmo.2011.11.012. Epub 2011 Nov 30.</citation>
    <PMID>22296973</PMID>
  </reference>
  <reference>
    <citation>Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, Elbers J, Gordon K, Mannaerts B; Pursue investigators. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril. 2015 Jul;104(1):94-103.e1. doi: 10.1016/j.fertnstert.2015.04.018. Epub 2015 May 21.</citation>
    <PMID>26003273</PMID>
  </reference>
  <reference>
    <citation>Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007 Jan;22(1):109-16. Epub 2006 Aug 26.</citation>
    <PMID>16936304</PMID>
  </reference>
  <reference>
    <citation>Cédrin-Durnerin I, Guivarc'h-Levêque A, Hugues JN; Groupe d'Etude en Médecine et Endocrinologie de la Reproduction. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012 Jun;97(6):1359-64.e1. doi: 10.1016/j.fertnstert.2012.02.028. Epub 2012 Mar 28.</citation>
    <PMID>22464760</PMID>
  </reference>
  <reference>
    <citation>Chang X, Wu J. Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders. Gynecol Endocrinol. 2013 Mar;29(3):196-200. doi: 10.3109/09513590.2012.736558. Epub 2012 Nov 30.</citation>
    <PMID>23194136</PMID>
  </reference>
  <reference>
    <citation>Escriva AM, Diaz-Garcia C, Monterde M, Rubio JM, Pellicer A. Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM). J Clin Endocrinol Metab. 2015 Jul;100(7):2597-605. doi: 10.1210/jc.2015-1194. Epub 2015 May 8.</citation>
    <PMID>25955224</PMID>
  </reference>
  <reference>
    <citation>Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003 Dec;18(12):2698-703.</citation>
    <PMID>14645194</PMID>
  </reference>
  <reference>
    <citation>Guivarc'h-Levêque A, Homer L, Arvis P, Broux PL, Moy L, Priou G, Vialard J, Colleu D, Dewailly D. Programming in vitro fertilization retrievals during working days after a gonadotropin-releasing hormone antagonist protocol with estrogen pretreatment: does the length of exposure to estradiol impact on controlled ovarian hyperstimulation outcomes? Fertil Steril. 2011 Oct;96(4):872-6. doi: 10.1016/j.fertnstert.2011.07.1138. Epub 2011 Aug 24.</citation>
    <PMID>21868004</PMID>
  </reference>
  <reference>
    <citation>Hauzman EE, Zapata A, Bermejo A, Iglesias C, Pellicer A, Garcia-Velasco JA. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod Biol Endocrinol. 2013 Sep 28;11:96. doi: 10.1186/1477-7827-11-96.</citation>
    <PMID>24074027</PMID>
  </reference>
  <reference>
    <citation>Nielsen AP, Korsholm AS, Lemmen JG, Sylvest R, Sopa N, Nyboe Andersen A. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone. Gynecol Endocrinol. 2016 Aug;32(8):625-628. Epub 2016 Feb 18.</citation>
    <PMID>26891977</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, Tournaye H. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod. 2013 May;28(5):1254-60. doi: 10.1093/humrep/det045. Epub 2013 Feb 26.</citation>
    <PMID>23442756</PMID>
  </reference>
  <reference>
    <citation>Reynolds KA, Omurtag KR, Jimenez PT, Rhee JS, Tuuli MG, Jungheim ES. Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. Hum Reprod. 2013 Nov;28(11):2981-9. doi: 10.1093/humrep/det306. Epub 2013 Jul 25. Review.</citation>
    <PMID>23887073</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Anne GUIVARC'H-LEVEQUE</investigator_full_name>
    <investigator_title>Reproductive Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>Fertility</keyword>
  <keyword>Reproductive processes</keyword>
  <keyword>In vitro fertilization</keyword>
  <keyword>Intracytoplasmic sperm injection</keyword>
  <keyword>Estrogens</keyword>
  <keyword>Follicule Stimulating Hormon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

